Urinary concentrations and urine ex-vivo effect of mecillinam and sulphamethizole

Clinical Microbiology and Infection

Volumn 10, Issue 1, 2004, Pages 54-61

  Kerrn, M B ^a   Frimodt Moller N ^a   Espersen, F ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

Ex vivo; Mecillinam; Suphamethizole; Urinary concentrations

Indexed keywords

MECILLINAM; OXYTETRACYCLINE; PIVMECILLINAM; SULFAMETHIZOL OPHTHA; SULFAMETHIZOLE;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DEGRADATION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STRAIN DIFFERENCE; TABLET FORMULATION; URINARY TRACT INFECTION; VOLUNTEER;

ESCHERICHIA COLI;

EID: 1642422921     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.00737.x     Document Type: Article

References (36)

1. Stamey TA, Fair WR, Timothy MM, Millar MA, Mihara G, Lowery YC. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med 1974; 291: 1159-1163.
2. Anderson JD. The relevance of urine and serum antibacterial activity to the treatment of urinary tract infections. J Antimicrob Chemother 1976; 2: 226-228.
3. Klastersky J, Daneau D, Swings G, Weerts D. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J Infect Dis 1974; 129: 187-193.
4. Bergan T. Valg av sulfonamider basert på deres kjemiske og farmakokinetiske egenskaper. Norsk Farm Tidsskrift 1973; 81: 387-395.
5. Roholt K. Pharmacokinetic studies with mecillinam and pivmecillinam. J Antimicrob Chemother 1977; 3(suppl 13): 71-81.
6. Bratton AC, Marshall EK. A new coupling component for sulfanilamide determination. J Biol Chem 1939; 122: 537-550.
7. Jacobs MR, Robinson RG, Koornhof HJ. Antibacterial activity of nitroxoline and sulfamethizole alone and in combination in urinary tract infections. South Afr Med J 1978; 54: 959-962.
8. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th edn. Approved standard M7-A5. Villanova, Pa: NCCLS, 2000.
9. Kerrn MB, Klemmensen T, Frimodt-Møller N, Espersen F. Susceptibility of Danish Escherichia coli strains isolated from urinary tract infections and bacteraemia, and distribution of sul genes conferring sulphonamide resistance. J Antimicrob Chemother 2002; 50: 513-516.
10. Weinstein L, Madoff MA, Samet CM. The sulfonamides. N Engl J Med 1960; 263: 793-800.
11. Welling PG, Craig WA, Amidon GL, Kunin CM. Pharmacokinetics of trimethoprim and sulfamethoxazole in normal subjects and in patients with renal failure. J Infect Dis 1973; 128(suppl): S556-S566.
12. Bach MC, Gold O, Finland M. Absorption and urinary execretion of trimethoprim, sulfamethoxazole, and trimethoprim-sulfamethoxazole: results with single doses in normal young adults and preliminary observations during therapy with trimethoprim-sulfamethoxazole. J Infect Dis 1973; 128(suppl): S584-S599.
13. Parson RL, Hossack GM, Paddock GM. Plasma profile and urinary excretion of mecillinam after pivmecillinam. In: Connots TA, Williams JD, Geddes AM, Hellmann K eds. Chemotherapy. New York: Plenum Press, 1976; 173-181.
14. Roholt K, Nielsen B, Kristensen E. Pharmacokinetic studies with mecillinam and pivmecillinam. Chemotherapy 1975; 21: 146-166.
15. Heikkila A, Pyykko K, Erkkola R, Iisalo E. The pharmacokinetics of mecillinam and pivmecillinam in pregnant and non-pregnant women. Br J Clin Pharmacol 1992; 33: 629-633.
16. Neu HC, Srinivasan S, Francke EL, Ortiz Neu C, Christenson JG. Pharmacokinetics of amdinocillin and pivamdinocillin in normal volunteers. Am J Med 1983; 75: 60-64.
17. Williams JD, Andrews J, Mitchard M, Kendall MJ. Bacteriology and pharmacokinetics of the new amidino penicillin mecillinam. J Antimicrob Chemother 1976; 2: 61-69.
18. Wise R, Pippard M, Reeves DS. A laboratory and clinical investigation of mecillinam and its ester pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother 1977; 3(suppl B): 113-120.
19. Anderson JD, Adams MA. Urinary excretion of mecillinam by volunteers receiving film-coated tablets of pivmecillinam hydrochloride. Chemotherapy 1979; 25: 1-4.
20. Johansen KS, Grosen G, Holm Nielsen E et al. Patients with symptoms of acute urinary infections treated with piromidic acid or sulfamethizole in general practice. A double-blind clinical controlled multicentre study. Ugeskr Laeger 1981; 143: 2491-2494.
21. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; MIC interpretive standards (μg/mL) for Enterobacteriaceae. Approved standard M100-S12. Villanova, Pa: NCCLS, 2001.
22. Mabeck CE, Vejlsgaard R. Treatment of urinary tract infections in general practice with sulfamethizole, trimethoprim or co-trimazine (sulphadiazine-trimethoprim). J Antimicrob Chemother 1980; 6: 701-708.
23. Andersen B, Bonderup OK, Tilma A. Urinary tract infection in general practice treated with sulfamethizole in a single dose or for 6 days. Ugeskr Laeger 1986; 148: 511-513.
24. Bergan T, Skjerven O. Double blind comparison of short and medium term sulfonamides, sulfamethizole and sulfamethoxazole, in uncomplicated acute urinary tract infections. Scand J Infect Dis 1979; 11: 219-223.
25. Clarke PD, Geddes AM, McGhie D, Wall JC. Pivmecillinam in urinary tract infections: a correlation of urinary bactericidal activity with clinical efficacy. J Antimicrob Chemother 1977; 3: 169-173.
26. Bresky B. Controlled randomized study comparing amoxycillin and pivmecillinam in adult out-patients presenting with symptoms of acute urinary tract infection. J Antimicrob Chemother 1977; 3(suppl B): 121-127.
27. Guttmann D. A comparison of pivmecillinam and cotrimoxazole in the treatment of simple cystitis in general practice. J Antimicrob Chemother 1977; 3(suppl B): 137-140.
28. Mabeck CE. Treatment of uncomplicated urinary tract infection in non-pregnant women. Postgrad Med J 1972; 48: 69-75.
29. Menday AP. Comparison of pivmecillinam and cephalexin in acute uncomplicated urinary tract infection. Int J Antimicrob Agents 2000; 13: 183-187.
30. Pitkajarvi T, Pyykonen ML, Kannisto K, Piippo T, Viita P. Pivmecillinam treatment in acute cystitis. Three versus seven days study. Arzneimittelforschung 1990; 40: 1156-1158.
31. Skinner JL, Venables TL, Sheldon MG. A general practice evaluation of pivmecillinam given twice daily as a treatment for acute urinary tract infection. Pharmatherapeutica 1984; 4: 25-31.
32. Bitsch M, Hansen PH, Pagh J. Treatment of acute urinary infections. Comparison between pivmecillinam for 3 days and sulfamethizole therapy for 6 days. Ugeskr Laeger 1985; 147: 1392-1395.
33. Madsen ST. Antibacterial effect of urine after single oral doses of sulfonamide. Chemotherapy 1968; 13: 16-22.
34. Naber KG, Theuretzbacher U, Kinzig M, Savov O, Sorgel F. Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 1659-1665.
35. Well M, Naber KG, Kinzig-Schippers M, Sorgel F. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. Int J Antimicrob Agents 1998; 10: 31-38.
36. Broughall JM, Bywater MJ, Holt HA, Reeves DS. Bactericidal or bacteristatic effects of two sulphonamide plus trimethoprim preparations in human urine. Infection 1979; 7: 113-118.